EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease — Stella

Home/Intervertebral Disc Degeneration/

View on ClinicalTrials.gov

Recruiting

Back to Intervertebral Disc Degeneration trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Taiwan

Taipei Medical University Hospital Clinical Research Center, Taipei

Key details

Phase

Early testing / Safety & dosing

Sponsor

ASTEROGENE Biomedical Co. Ltd.

Enrollment target

~12 participants

Started

September 2025

Primary completion

December 2026

Age range

20 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.